异麦芽糖酐铁与蔗糖铁治疗缺铁性贫血的随机试验
这项开放标签、多中心随机试验将511例口服铁不耐受或无应答的缺铁性贫血患者按2:1随机分配至异麦芽糖酐铁或蔗糖铁组,随访5周。主要终点为第1-5周内血红蛋白(Hb)较基线升高≥2 g/dL的患者比例,非劣效性和优效性均得到确认,异麦芽糖酐铁组达到Hb升高≥2 g/dL的时间更短。两种治疗均耐受良好,0.6%发生严重药物不良反应。
要点
- 异麦芽糖酐铁在主要终点(Hb升高≥2 g/dL的患者比例)上非劣效且优效于蔗糖铁。
- 异麦芽糖酐铁达到Hb升高≥2 g/dL的时间更短,所有生化疗效指标改善更快和/或更明显。
- 异麦芽糖酐铁允许更高累积剂量、更少给药次数;两种治疗均耐受良好,0.6%发生严重药物不良反应。
核心结论
- 异麦芽糖酐铁在实现Hb快速改善方面比蔗糖铁更有效。
- 异麦芽糖酐铁相比蔗糖铁的优势在于允许更高累积剂量、更少给药次数。
- 两种治疗在广泛的缺铁性贫血人群中均耐受良好。
研究设计与样本
- 开放标签、对照、多中心随机试验。
- 511例不同病因的缺铁性贫血患者,按2:1随机分配至异麦芽糖酐铁或蔗糖铁组,随访5周。
- 异麦芽糖酐铁累积剂量基于体重和血红蛋白(Hb),给药方式为1000 mg输注超过15分钟或500 mg注射超过2分钟。
- 蔗糖铁累积剂量按Ganzoni公式计算,以重复200 mg输注30分钟给药。
主要发现
- 异麦芽糖酐铁平均累积剂量为1640.2(标准差357.6)mg,蔗糖铁为1127.9(标准差343.3)mg。
- 主要终点为第1-5周内任何时间Hb较基线升高≥2 g/dL的患者比例,非劣效性和优效性均得到确认。
- 异麦芽糖酐铁组达到Hb升高≥2 g/dL的时间更短。
- 所有生化疗效参数均显示异麦芽糖酐铁改善更快和/或更明显。
- 两种治疗均耐受良好;0.6%发生严重药物不良反应。
关键数值与推荐
- 主要终点:第1-5周内任何时间Hb较基线升高≥2 g/dL的患者比例。
- 异麦芽糖酐铁累积剂量基于体重和Hb,可为1000 mg输注超过15分钟或500 mg注射超过2分钟。
- 蔗糖铁累积剂量按Ganzoni公式计算,以重复200 mg输注30分钟给药。
临床怎么用
- 对于口服铁不耐受或无应答的缺铁性贫血患者,异麦芽糖酐铁可比蔗糖铁更快改善Hb。
- 异麦芽糖酐铁允许更高累积剂量和更少给药次数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency anemia (IDA) is common in many chronic diseases, and intravenous (IV) iron offers a rapid and efficient iron correction. This trial compared the efficacy and safety of iron isomaltoside (also known as ferric derisomaltose) and iron sucrose in patients with IDA who were intolerant of, or unresponsive to, oral iron. The trial was an open‐label, comparative, multi‐center trial. Five hundred and eleven patients with IDA from different causes were randomized 2:1 to iron isomaltoside or iron sucrose and followed for 5 weeks. The cumulative dose of iron isomaltoside was based on body weight and hemoglobin (Hb), administered as either a 1000 mg infusion over more than 15 minutes or 500 mg injection over 2 minutes. The cumulative dose of iron sucrose was calculated according to Ganzoni and administered as repeated 200 mg infusions over 30 minutes. The mean cumulative dose of iron isomaltoside was 1640.2 (standard deviation (SD): 357.6) mg and of iron sucrose 1127.9 (SD: 343.3) mg. The primary endpoint was the proportion of patients with a Hb increase ≥2 g/dL from baseline at any time between weeks 1‐5. Both non‐inferiority and superiority were confirmed for the primary endpoint, and a shorter time to Hb increase ≥2 g/dL was observed with iron isomaltoside. For all biochemical efficacy parameters, faster and/or greater improvements were found with iron isomaltoside. Both treatments were well tolerated; 0.6% experienced a serious adverse drug reaction. Iron isomaltoside was more effective than iron sucrose in achieving a rapid improvement in Hb. Furthermore, iron isomaltoside has an advantage over iron sucrose in allowing higher cumulative dosing in fewer administrations. Both treatments were well tolerated in a broad population with IDA.
引用
- Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017. PMID: 28052413. doi:10.1002/ajh.24633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。